NovaBridge Biosciences (NBP) SEC Filings & Earnings Calls
EquiReason read 36 NovaBridge Biosciences SEC filings in the last 12 months. Latest: 6-K on 2026-10-23 — Clinical data from ongoing Phase 1 trial of ragistomig (PD-L1x4-1BB bispecific antibody) presented at ESMO 2026 by ABL Bio. No efficacy or safety results disclosed in the filing; o.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 365.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Apr, in 163 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
23 Oct 20266-KClinical data from ongoing Phase 1 trial of ragistomig (PD-L1x4-1BB bispecific antibody) presented at ESMO 2026 by ABL Bio. No efficacy or safety results disclosed in the filing; only that data were presented.open
Risks flagged
No efficacy or safety data disclosed; early-stage trial with binary outcome risk.
“No specific results provided in the filing; only that data were presented.”
13 Oct 20266-KVisara (NovaBridge subsidiary) in-licenses VIS-102 (HT006.2.2) from Hiteck for NK; $7M upfront + up to $104M milestones + tiered royalties; Phase 1b data shows 50% complete corneal healing vs 14% control.open
Figures in the filing · each found in the filing text
| upfront and near-term milestone payment · Q4-2026 | $7M | |
| additional aggregate milestone payments | $104M | |
| complete corneal healing rate (highest dose cohort) | 50.0% | |
| complete corneal healing rate (vehicle control) | 14.0% |
Risks flagged
Clinical and regulatory risk for VIS-102; only Phase 1b data available, further trials needed.
“VIS-102 is an investigational therapy; Phase 1b data is early-stage and may not predict later trial outcomes.”
Milestone and royalty payment obligations could strain cash flows if development is delayed or fails.
“Up to $104M in additional milestone payments plus tiered royalties on net sales.”
20 Aug 20266-KFiling is a 6-K furnishing an investor presentation; no material financial or operational event disclosed.open
Risks flagged
No new risk signals; filing contains only boilerplate risk factors.
“Standard forward-looking statement disclaimers.”
17 Jul 20266-KNovaBridge Biosciences adopts 2026 Omnibus Share Incentive Plan authorizing 11,960,000 shares for equity awards; routine equity incentive plan adoption for a foreign private issuer.open
Risks flagged
Potential dilution from future equity awards under the 2026 Plan, but capped at 3% of outstanding shares annually.
“Maximum aggregate shares initially 11,960,000; annual increase limited to 3% of outstanding shares.”
29 Jun 20266-KNovaBridge Biosciences appointed Dr. Srishti Gupta as CEO effective July 1, 2026, succeeding Xi-Yong Fu; also board resignations and President role change.open
Risks flagged
Leadership transition risk; departure of CEO and board members may cause short-term uncertainty.
“CEO resignation and two board members resigned effective June 30, 2026.”
16 Jun 20266-KChange in independent auditor from PwC to Deloitte; no disagreements or reportable events.open
Risks flagged
Auditor change could signal underlying issues, but no disagreements reported.
“Change from PwC to Deloitte, no adverse opinions or disagreements.”
16 Jun 202620-F/ANovaBridge Biosciences filed an amendment to its 20-F solely to correct beneficial ownership disclosure errors; no financial or operational impact.open
Figures in the filing · each found in the filing text
| Ordinary shares outstanding · 2025-12-31 | 265,377,891 |
7 Apr 20266-KNovaBridge Biosciences reports FY2025 results with strong cash position ($210.8M), positive clinical data for givastomig and VIS-101, and potential FDA accelerated approval pathway for givastomig.earningsopen
Figures in the filing · each found in the filing text
| Cash and cash equivalents · FY2025 | $211M |
Risks flagged
Clinical and regulatory risk for pipeline programs; dependency on successful Phase 3 outcomes.
“Pipeline stage; potential accelerated approval pathway not guaranteed.”
7 Apr 202620-FNovaBridge Biosciences (formerly I-Mab) reports positive clinical data for givastomig and VIS-101, FDA alignment on accelerated approval pathway for givastomig, and adoption of new platform business model.open
Figures in the filing · each found in the filing text
| Net Loss from Continuing Operations · FY2025 | $-88M | +78% y/y |
| Research and Development Expenses · FY2025 | $63M | +189% y/y |
| Cash and Cash Equivalents · FY2025 | $211M | |
| Net Cash Used in Operating Activities from Continuing Operations · FY2025 | $-21M | -61% y/y |
Risks flagged
Drug Pricing Pressure
“The IRA, among other things, (i) directs the Secretary of the HHS to negotiate through the Medicare Drug Negotiation Program, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation.” · word for word
Regulatory Compliance Cost
“We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations.” · word for word
Reimbursement Uncertainty
“Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval.” · word for word
16 Mar 20266-KFDA confirms givastomig's potential eligibility for accelerated approval pathway in 1L gastric cancer; registrational Phase 3 trial expected Q4 2026.open
Figures in the filing · each found in the filing text
| Objective response rate (Phase 1b) · Phase 1b | 75.0% | |
| Median progression free survival · Phase 1b | $16.90 | |
| 6-month landmark PFS rate · Phase 1b | 82.0% |
Risks flagged
Clinical and regulatory risk: accelerated approval pathway still requires successful Phase 3 trial.
“NovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026” · word for word
Competition risk: multiple CLDN18.2 targeting therapies in development.
“Givastomig, a bispecific Claudin 18.2 X 4-1BB antibody, has the potential to be a first-in-class and best-in-class” · word for word
9 Mar 20266-KPositive Phase 2a topline results for VIS-101 in wet AMD: mean BCVA improvement >10 letters, median CST reduction 100-150 µm, ~2/3 retreatment-free at 4 months, ~1/2 at 6 months, favorable safety.open
Figures in the filing · each found in the filing text
| BCVA improvement · wet AMD · Phase 2a | $10.00 |
Risks flagged
Phase 2a data may not replicate in larger Phase 2b/3 trials
“Small sample size (n=38); Phase 2b and Phase 3 still to come”
Competitive landscape with existing dual inhibitors like faricimab
“Faricimab already established as standard of care for dual VEGF-A/ANG-2 inhibition”
17 Feb 20266-KFirst patient dosed in Phase 2 study of givastomig for 1L metastatic gastric cancer; Phase 1b showed 75% ORR, 16.9-month mPFS, 82% 6-month PFS.open
Figures in the filing · each found in the filing text
| objective response rate · 1L metastatic gastric cancer · Phase 1b | 75.0% | |
| median progression free survival · 1L metastatic gastric cancer · Phase 1b | $16.90 | |
| six-month landmark PFS · 1L metastatic gastric cancer · Phase 1b | 82.0% |
6 Jan 20266-KPositive Phase 1b data for givastomig in 1L gastric cancer: 77% ORR at 8 mg/kg, 73% at 12 mg/kg, median PFS 16.9 months at 8 mg/kg. Potential best-in-class.open
Figures in the filing · each found in the filing text
| ORR · 8 mg/kg · Phase 1b dose ex | 77.0% | |
| ORR · 12 mg/kg · Phase 1b dose ex | 73.0% | |
| median PFS · 8 mg/kg · Phase 1b dose ex | $16.90 | |
| DCR · 8 mg/kg · Phase 1b dose ex | 96.0% | |
| DCR · 12 mg/kg · Phase 1b dose ex | 100.0% |
Risks flagged
Phase 1b data, need confirmatory Phase 2/3.
“NovaBridge is on track to initiate enrollment in a global, randomized Phase 2 study” · word for word
10 Dec 20256-KPositive Phase 1 dose expansion data for ragistomig at ESMO-IO: Q6W dosing shows comparable efficacy with improved safety (5% Grade≥3 LFT vs 40% Q2W).open
Figures in the filing · each found in the filing text
| Disease Control Rate (DCR) at 3 mg/kg Q6W · ragistomig · Phase 1 Q6W | 58.8% | |
| Objective Response Rate (ORR) at 3 mg/kg Q6W · ragistomig · Phase 1 Q6W | 11.8% | |
| Grade ≥3 LFT elevation at 3 mg/kg Q6W · ragistomig · Phase 1 Q6W | 5.0% |
31 Oct 20256-KNovaBridge Biosciences filed supplemental disclosures for a proposed dual primary listing on the Hong Kong Stock Exchange and an IPO. No financial results or material changes disclosed.open
Risks flagged
No assurance that the proposed HKEX listing and IPO will occur.
“There is no assurance as to if or when the Listing and Offering will take place.” · word for word
30 Oct 20256-KNovaBridge subsidiary Visara assigned its exclusive license for VIS-101 (wet AMD treatment) to Everest Medicines for Greater China and other Asian markets. Also appointed Everest's President/CFO to its Board.open
Risks flagged
VIS-101 is still in Phase 2; no guarantee of successful development or commercialization.
“The program is completing a Phase 2 study in China and is expected to be Phase-3-ready in 2026.” · word for word
29 Oct 20256-KI-MAB changed its name to NovaBridge Biosciences and ticker to NBP, effective October 30, 2025, reflecting a strategic transformation to a global biotech platform with a hub-and-spoke model.open
Risks flagged
No assurance that the proposed HKEX listing will occur.
“Our proposed dual listing on both Nasdaq and HKEX... will enable us to broaden and diversify our investor base... (forward-looking statement)” · word for word
28 Oct 20256-KI-MAB (now NovaBridge) closed the acquisition of Bridge Health Biotech for $1.8M upfront plus potential milestones up to $3.875M, gaining rights to CLDN18.2 bispecific and multi-specific applications.acquisitionopen
Risks flagged
Acquisition is small and contingent on development milestones; no guarantee of success.
“Bridge Health shareholders may receive future milestone payments of up to $3.875 million, subject to the achievement of certain development and regulatory milestones.” · word for word
24 Oct 20256-KUpdated Phase 1 data for givastomig monotherapy in CLDN18.2+ GEC shows 18% ORR, favorable safety, and responses across expression levels.open
Figures in the filing · each found in the filing text
| Objective Response Rate · CLDN18.2+ GEC · 2025-08-27 | 18.0% | |
| Disease Control Rate · CLDN18.2+ GEC · 2025-08-27 | 49.0% | |
| Median Progression Free Survival · CLDN18.2+ GEC · 2025-08-27 | $2.96 | |
| Median Overall Survival · CLDN18.2+ GEC · 2025-08-27 | $7.49 |
Risks flagged
Phase 1 data limited by small sample size and lack of comparator; further validation needed.
“45 patients, single-arm study; median prior therapies 3.”
24 Oct 20256-KShareholders approved name change from I-Mab to NovaBridge Biosciences and adoption of seventh amended and restated memorandum and articles of association at EGM on October 24, 2025.open
Risks flagged
No material risk signals identified; filing relates to corporate name change and governance update.
NovaBridge Biosciences — questions
- What did NovaBridge Biosciences file recently?
- 36 SEC filings in the last 12 months. Latest: 6-K on 2026-10-23 — Clinical data from ongoing Phase 1 trial of ragistomig (PD-L1x4-1BB bispecific antibody) presented at ESMO 2026 by ABL Bio. No efficacy or safety results disclosed in the filing; only that data were presented.
Every figure on this page comes from NovaBridge Biosciences's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.